First Injectable Treatment for HIV Pre-Exposure Prevention Approved

THE United States (US) Food and Drug Administration approved Apretude or use in at-risk adults and adolescents weighing at least 35 kilograms (77 pounds) for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV. Apretude is given first as two initiation injections administered one month apart, and then every two months thereafter. Patients can either start their treatment with Apretude or take oral cabotegravir (Vocabria) for four weeks to assess how well they tolerate the drug. Own Correspondent “Today’s approval adds an important tool in the effort to…

Read More